1,3-Oxazines as BACE1 and/or BACE2 inhibitors: a patent evaluation (WO2012156284)

Bibliography

• Moller HJ, Graeber MB. The case described by Alois Alzheimer in 1911. Historical and conceptual perspectives based on the clinical record and neurohistological sections. Eur Arch Psychiatry Clin Neurosci 1998;248:111-22
   PubMed Web of Science ®Google Scholar
• Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 2010;9:387-98
   PubMed Web of Science ®Google Scholar
• Thies W, Bleiler L. 2011 Alzheimer's disease facts and figures. Alzheimers Dement 2011;7:208-44
   PubMed Web of Science ®Google Scholar
• Hardy J, Allsop D. Amyloid deposition as the central event in the etiology of Alzheimer's disease. Trends Pharmacol Sci 1991;12:383-8
   PubMed Web of Science ®Google Scholar
• Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184-5
   PubMed Web of Science ®Google Scholar
• Kung HF. The beta-amyloid hypothesis in Alzheimer's disease: seeing is believing. ACS Med Chem Lett 2012;3:265-7
   PubMed Web of Science ®Google Scholar
• Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem 2007;101:1172-84
   PubMed Web of Science ®Google Scholar
• De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 2010;6:99-107
   PubMed Web of Science ®Google Scholar
• Available from: ClinicalTrials.gov Indentifier:NCT01739348
   Google Scholar
• Available from: ClinicalTrials.gov Identifier:NCT01561430
   Google Scholar
• Available from: ClinicalTrials.gov Identifier:NCT01600859
   Google Scholar
• Available from: ClinicalTrials.gov Identifier:NCT01592331
   Google Scholar
• Available from: ClinicalTrials.gov Identifier:NCT01795339
   Google Scholar
• F. Hoffmann-La Roche AG and Siena Biotech S.P.A. Preparation of 1,3-oxazines as BACE1 and BACE2 inhibitors. WO2012156284A1; 2012
   Google Scholar
• F. Hoffmann-La Roche AG. N-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexahydro-cyclopenta[e][1,3]oxazin-4-yl)-phenyl)-amides as bace1 inhibitors. WO2013041499A1; 2013
   Google Scholar
• F. Hoffmann-La Roche AG and Siena Biotech S.P.A. Preparation of cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors. WO2013004676A1; 2013
   Google Scholar
• F. Hoffmann-La Roche AG. [1,3]Oxazines as BACE inhibitors and their preparation and use as imaging agents and in the treatment of Alzheimer's disease and diabetes. WO2012168175A1; 2012
   Google Scholar
• F. Hoffmann-La Roche AG and Siena Biotech S.P.A. Halogen-alkyl-1,3 oxazines as BACE1 and/or BACE2 inhibitors and their preparation. WO2012168164A1; 2012
   Google Scholar
• F. Hoffmann-La Roche AG. Spiro[1,3]oxazines and spiro[1,4]oxazepines as BACE1 and/or BACE2 inhibitors and their preparation. US20120302549A1; 2012
   Google Scholar
• F. Hoffmann-La Roche AG. Preparation of 1,3-oxazines as BACE1 and/or BACE2 inhibitors. US20120258962A1; 2012
   Google Scholar
• F. Hoffmann-La Roche AG and Siena Biotech S.P.A. Preparation of 1,4-oxazepines as therapeutic BACE1 and/or BACE2 inhibitors. US20120253035A1; 2012
   Google Scholar
• F. Hoffmann-La Roche AG and Siena Biotech S.P.A. 1,4-Oxazepine derivatives as BACE1 and BACE2 inhibitors and their preparation and use for the treatment of Alzheimer's disease and type 2 diabetes. US20120238548A1; 2012
   Google Scholar
• F. Hoffmann-La Roche AG. Preparation of 1,4-thiazepines/sulfones as therapeutic BACE1 and/or BACE2 inhibitors. US20120225858A1; 2012
   Google Scholar
• F. Hoffmann-La Roche AG and Siena Biotech S.P.A. 1,4-Oxazines as BACE1 and/or BACE2 inhibitors and their preparation. US20120184540A1; 2012
   Google Scholar
• F. Hoffmann-La Roche AG and Siena Biotech S.P.A. Preparation of oxazepine derivatives for use as BACE1 and/or BACE2 inhibitors. WO2012110459A1; 2012
   Google Scholar
• F. Hoffmann-La Roche AG. Preparation of N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-azainden-7-yl)phenyl] amides as BACE1 and BACE2 inhibitors. US20120202803A1; 2012
   Google Scholar
• F. Hoffmann-La Roche AG and Siena Biotech S.P.A. Preparation of 1,4-oxazines as therapeutic BACE1 and/or BACE2 inhibitors. US20120196863A1; 2012
   Google Scholar
• F. Hoffmann-La Roche AG and Siena Biotech S.P.A. Preparation of 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds as therapeutic BACE1 and BACE2 inhibitors. WO2011138293A1; 2011
   Google Scholar
• F. Hoffmann-La Roche AG and Siena Biotech S.P.A. Preparation of 2-amino-5,5-difluoro-5,6-dihydro-4H-oxazine derivatives as BACE1 and/or BACE2 inhibitors. WO2011069934A1; 2011
   Google Scholar
• F. Hoffmann-La Roche AG and Siena Biotech S.P.A. Preparation of 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazine derivatives as therapeutic BACE1 and/or BACE2 inhibitors. WO2011020806A1; 2011
   Google Scholar
• F. Hoffmann-La Roche, Inc. and Siena Biotech S.P.A. Preparation of 4,4-diphenyl-4,5-dihydro-oxazol-2-ylamine derivatives as beta-secretase inhibitors. US20090209529A1; 2009
   Google Scholar
• Shionogi & Co., Ltd. Preparation of 2-amino-4-phenyl-4,5-dihydro-5H-1,3-thiazine derivatives and related compounds for treatment of Alzheimer's disease. WO2008133273A1; 2008
   Google Scholar
• National Diabetes Information Clearinghouse (NDIC). A service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH). Available from: http://www.diabetes.niddk.nih.gov/dm/pubs/statistics/#fast
   Google Scholar
• Akpinar P, Kuwajima S, Krutzfeldt J, et al. Tmem27: a cleaved and shed plasma membrane protein that stimulates pancreatic beta cell proliferation. Cell Metab 2005;2:385-97
   PubMed Web of Science ®Google Scholar
• Esterhazy D, Stuetzer I, Wang H, et al. Bace2 Is a beta cell-enriched protease that regulates pancreatic beta cell function and mass. Cell Metab 2011;14:365-77
   PubMed Web of Science ®Google Scholar
• Southan C. BACE2 as a new diabetes target: a patent review 2010 - 2012. Expert Opin Ther Pat 2013;23:649-63
   PubMed Web of Science ®Google Scholar
• Stamford AW, Scott JD, Li SW, et al. Discovery of an orally available, brain penetrant BACE1 inhibitor that affords robust CNS A-beta reduction. ACS Med Chem Lett 2012;3:897-902
   PubMed Web of Science ®Google Scholar
• Hilpert H, Guba W, Woltering TJ, et al. beta-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease. J Med Chem 2013;56:3980-95
   PubMed Web of Science ®Google Scholar
• Probst G, Xu Y-Z. Small-molecule BACE1 inhibitors: a patent literature review (2006 - 2011). Expert Opin Ther Pat 2012;22:511-40
   PubMed Web of Science ®Google Scholar
• Evin G, Lessene G, Wilkins S. BACE inhibitors as potential drugs for the treatment of Alzheimer's disease: focus on bioactivity. Recent Pat CNS Drug Discov 2011;6:91-106
   PubMedGoogle Scholar
• Albala B, Kaplow J, Majid O, et al. Novel BACE1 Inhibitor E2609 Reduces Plasma and CSF Amyloid in Healthy Subjects after 14 Days Oral Administration. AD/PD 2013 The 11th International Conference on Alzheimer's & Parkinson's Diseases; 6–10 March 2013; Eisai, Florence, Italy
   Google Scholar
• Palcza J, Tseng J, Dockendorf M, et al. The Novel BACE Inhibitor MK-8931 Dramatically Lowers CSF A-beta Peptide in Patients with Mild to Moderate Alzheimer's Disease [Abstract PL02.004]. AD/PD 2013, The 11th Annual International Conference on Alzheimer's and Parkinson's Diseases; 6–10 March 2013; Merck, Florence, Italy
   Google Scholar
• Willis BA, Komjathy SF, Gonzales CR, et al. Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of BACE Inhibitor LY2886721 in Healthy Volunteers (HVs) at Steady State [Abstract P01.017]. American Academy of Neurology (AAN) 65th Annual Meeting; 16–23 March 2013; Eli Lilly and Co., San Diego, California
   Google Scholar